Deerfield Mgmt Updates Nuo Therapeutics Stake in 13G/A Filing

TL;DR

**Deerfield Mgmt updated their Nuo Therapeutics stake, showing continued institutional interest.**

AI Summary

Deerfield Mgmt, L.P. filed an amended Schedule 13G/A on February 12, 2024, indicating their ownership of Nuo Therapeutics, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous statement, updates their beneficial ownership information. For investors, this matters because it provides transparency into a significant institutional holder's position, potentially signaling their ongoing interest or changes in their investment thesis for Nuo Therapeutics.

Why It Matters

This filing shows that Deerfield Mgmt, L.P. continues to hold a position in Nuo Therapeutics, Inc., offering insight into a major investor's ongoing involvement with the company.

Risk Assessment

Risk Level: low — This is a routine amendment to a beneficial ownership filing, indicating no immediate high-risk events for the company.

Analyst Insight

An investor should note Deerfield Mgmt's continued presence as a holder, but this filing alone doesn't provide enough information to make a buy/sell decision. Further research into Nuo Therapeutics' financials and business developments would be prudent.

Key Numbers

• 67059V209 — CUSIP Number (identifies Nuo Therapeutics, Inc. Common Stock)
• 20240212 — Filing Date (the date the SC 13G/A was filed with the SEC)
• 20231231 — Date of Event (the date as of which the ownership information is reported)
• 0001193805-24-000195 — Accession Number (unique identifier for this specific SEC filing)
• 005-62061 — SEC File Number (identifies Nuo Therapeutics, Inc. with the SEC)

Key Players & Entities

• Deerfield Mgmt, L.P. (company) — reporting person and beneficial owner of Nuo Therapeutics, Inc. stock
• Nuo Therapeutics, Inc. (company) — the issuer whose securities are being reported
• Flynn James E (person) — filer of the SC 13G/A
• Deerfield Management Company, L.P. (company) — group member associated with the reporting person
• Deerfield PDI Financing II, L.P. (company) — group member associated with the reporting person

Forward-Looking Statements

• Deerfield Mgmt, L.P. will maintain a significant stake in Nuo Therapeutics, Inc. for the foreseeable future. (Deerfield Mgmt, L.P.) — medium confidence, target: 2025-12-31
• Nuo Therapeutics, Inc. will continue to be listed under the CUSIP 67059V209. (Nuo Therapeutics, Inc.) — high confidence, target: 2024-12-31

FAQ

Filing Documents

• e619264_sc13ga-nti.htm (SC 13G/A) — 111KB
• 0001193805-24-000195.txt ( ) — 112KB

(a)

Item 1(a). Name of Issuer: Nuo Therapeutics, Inc.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 8285 El Rio, Suite 190 Houston, TX 77054

(a)

Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Private Design Fund II, L.P., Deerfield PDI Financing II, L.P. and Deerfield Management Company, L.P.

(b)

Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Private Design Fund II, L.P., Deerfield PDI Financing II, L.P. and Deerfield Management Company, 345 Park Avenue South, 12th Floor, New York, NY 10010

(c)

Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Private Design Fund II, L.P. - Delaware limited partnerships; Deerfield PDI Financing II, L.P. – British Virgin Islands limited partnership; James E. Flynn – United States citizen

(d)

Item 2(d). Title of Class of Securities: Common Stock

(e)

Item 2(e). CUSIP Number: 67059V209 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); CUSIP No. 67059V209 13G Page 8 of 10 (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 2,183,164 shares Deerfield Management Company, L.P. - 2,183,164 shares Deerfield Private Design Fund II, L.P. - 1,016,934 shares Deerfield PDI Financing II, L.P. - 1,166,230 shares James E. Flynn – 2,183,164 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 5.16% Deerfield Management Company, L.P. - 5.16% Deerfield Private Design Fund II, L.P. – 2.76% Deerfield PDI Financing II, L.P. – 2.76% James E. Flynn – 5.16% (c) Number of shares as to which such perso

View Full Filing

View this SC 13G/A filing on SEC EDGAR